Document ID: chunk:federal_register_of_legislation:F2022L00259:reg:9:p3
Version: federal_register_of_legislation:F2022L00259
Segment Type: reg
Provision Reference: reg 9 (pt 3/4)
Character Range: 9858–12917

atherosclerotic disease and fibromuscular dysplasia.
(23)      having a solid organ, stem cell or bone marrow transplant before the clinical worsening of hypertension;
(24)      having diabetes mellitus for at least the 5 years before the clinical worsening of hypertension;
(25)      having chronic kidney disease at the time of the clinical worsening of hypertension;
Note: chronic kidney disease is defined in the Schedule 1 - Dictionary.
(26)      having an endocrine disorder from the specified list of endocrine disorders at the time of the clinical worsening of hypertension;
Note: specified list of endocrine disorders is defined in the Schedule 1 - Dictionary.
(27)      having sleep apnoea at the time of the clinical worsening of hypertension;
(28)      having extrinsic compression of the renal parenchyma from a haematoma or mass at the time of the clinical worsening of hypertension;
(29)      having:
            (a)          an aneurysm of the renal artery; or
            (b)          an arteriovenous fistula involving the blood supply of the kidney; or
            (c)          an arteriovenous malformation involving the blood supply of the kidney;
before the clinical worsening of hypertension;
(30)      having a clinically significant disorder of mental health as specified at the time of the clinical worsening of hypertension;
            Note: clinically significant disorder of mental health as specified is defined in the Schedule 1 – Dictionary.
(31)      taking a drug from the Specified List 1 of drugs, where that drug cannot be ceased or substituted, for a continuous period of at least the 28 days before the clinical worsening of hypertension;
Note: Specified List 1 of drugs is defined in the Schedule 1 - Dictionary.
(32)      taking a drug from the Specified List 2 of drugs at the time of the clinical worsening of hypertension;
Note: Specified List 2 of drugs is defined in the Schedule 1 - Dictionary.

         (33)      having glucocorticoid therapy as specified before the clinical worsening of hypertension, and if the glucocorticoid therapy as specified has ceased or decreased before the clinical worsening of hypertension, then that worsening occurred within 30 days of cessation or reduction of therapy;
Note: glucocorticoid therapy as specified is defined in the Schedule 1 - Dictionary.
(34)      taking medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection:
            (a)          for at least 28 days before the clinical worsening of hypertension; and
            (b)          if treatment has ceased before the clinical worsening of hypertension, then that worsening occurred within 30 days of cessation;
(35)      inability to undertake any physical activity greater than 3 METs for at least the 1 year before the clinical worsening of hypertension;
Note: MET is defined in the Schedule 1 - Dictionary.
(36)      being exposed to arsenic as specified before the clinical worsening of hypertension;
Note: being exposed to arsenic as specified